Skip to content
Nonprofiteer
← T A G TREATMENT ACTION GROUP INC

Form 990 for tax year 2023

Filed by T A G TREATMENT ACTION GROUP INC.

Totals

Total revenue
$4,736,176
Total expenses
$3,743,080
Contributions and grants received
$4,682,755
Grants paid
$296,958
Program service revenue
$43,188
Investment income
$9,829
Other revenue
$404
Total assets, end of year
$4,624,032
Total liabilities, end of year
$1,012,949
Net assets or fund balances, end of year
$3,611,083
Program services expenses (Part IX)
$2,964,703
Management and general expenses
$477,045
Fundraising expenses
$301,332
Program service expenses (Part III)
$2,964,703

Program services were 79.2% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.

Line items

Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.

Revenue

Part VIII, the statement of revenue.

  • 1c · Fundraising events

    $204,526

  • 1e · Government grants (contributions)

    $109,441

  • 1f · All other contributions, gifts and grants

    $4,368,788

  • 1g · Noncash contributions included above

    $5,874

  • 2a · Program service revenue: OTHER PROGRAM INCOME

    total $43,188 · related or exempt $43,188

  • 3 · Investment income

    total $9,829 · excluded $9,829

  • 8a · Fundraising events: gross income

    $37,625

  • 8a · Fundraising events: contributions included on line 1c

    $204,526

  • 8b · Fundraising events: direct expenses

    $37,625

  • 8c · Net income from fundraising events

    total $0

  • 10a · Gross sales of inventory

    $17,604

  • 10b · Cost of goods sold

    $17,200

  • 10c · Net income from sales of inventory

    total $404 · excluded $404

Functional expenses

Part IX, the statement of functional expenses.

  • 1 · Grants to domestic organizations and governments

    total $16,593 · program services $16,593

  • 3 · Grants to foreign organizations and individuals

    total $280,365 · program services $280,365

  • 5 · Compensation of officers, directors and key employees

    total $328,861 · program services $199,382 · management and general $66,387 · fundraising $63,092

  • 7 · Other salaries and wages

    total $1,459,285 · program services $1,143,658 · management and general $242,866 · fundraising $72,761

  • 9 · Other employee benefits

    total $405,456 · program services $312,123 · management and general $67,742 · fundraising $25,591

  • 10 · Payroll taxes

    total $131,391 · program services $99,140 · management and general $22,581 · fundraising $9,670

  • 11d · Fees: lobbying

    total $13,905 · management and general $13,905

  • 11g · Fees: other

    total $365,171 · program services $338,127 · management and general $15,270 · fundraising $11,774

  • 12 · Advertising and promotion

    total $1,986 · program services $120 · fundraising $1,866

  • 13 · Office expenses

    total $62,590 · program services $46,304 · management and general $5,039 · fundraising $11,247

  • 14 · Information technology

    total $34,490 · program services $28,506 · management and general $3,219 · fundraising $2,765

  • 16 · Occupancy

    total $161,682 · program services $121,818 · management and general $26,714 · fundraising $13,150

  • 17 · Travel

    total $238,403 · program services $218,176 · management and general $3,404 · fundraising $16,823

  • 19 · Conferences, conventions and meetings

    total $45,089 · program services $44,999 · fundraising $90

  • 22 · Depreciation, depletion and amortization

    total $5,564 · program services $4,191 · management and general $920 · fundraising $453

  • 23 · Insurance

    total $24,882 · program services $18,747 · management and general $4,111 · fundraising $2,024

  • 24a · Other expenses: FUNDRAISING EVENTS

    total $59,609 · fundraising $59,609

  • 24b · Other expenses: PRINTING & PUBLICATIONS

    total $51,747 · program services $44,448 · management and general $28 · fundraising $7,271

  • 24c · Other expenses: DUES AND SUBSCRIPTIONS

    total $44,644 · program services $43,731 · management and general $205 · fundraising $708

  • 24d · Other expenses: MISCELLANEOUS

    total $10,066 · program services $4,275 · management and general $3,353 · fundraising $2,438

  • 24e · All other expenses

    total $1,301 · management and general $1,301

Balance sheet

Part X, book values.

  • 1 · Cash, non-interest-bearing

    beginning of year $15,185 · end of year $48,553

  • 2 · Savings and temporary cash investments

    beginning of year $1,495,550 · end of year $1,394,085

  • 3 · Pledges and grants receivable

    beginning of year $555,526 · end of year $1,796,031

  • 4 · Accounts receivable

    beginning of year $3,756 · end of year $8,271

  • 9 · Prepaid expenses and deferred charges

    beginning of year $86,189 · end of year $72,871

  • 10a · Land, buildings and equipment: cost or other basis

    $98,526

  • 10b · Land, buildings and equipment: accumulated depreciation

    $84,961

  • 10c · Land, buildings and equipment, net

    beginning of year $15,931 · end of year $13,565

  • 15 · Other assets

    beginning of year $1,377,141 · end of year $1,290,656

  • 17 · Accounts payable and accrued expenses

    beginning of year $38,723 · end of year $74,007

  • 25 · Other liabilities

    beginning of year $892,568 · end of year $938,942

  • 27 · Net assets without donor restrictions

    beginning of year $1,965,644 · end of year $1,775,039

  • 28 · Net assets with donor restrictions

    beginning of year $652,343 · end of year $1,836,044

Mission and programs · 2023

Mission

TREATMENT ACTION GROUP (TAG) IS AN INDEPENDENT, ACTIVIST, AND COMMUNITY-BASED RESEARCH AND POLICY THINK TANK COMMITTED TO RACIAL, GENDER, AND LGBTQ+ EQUITY; SOCIAL JUSTICE; AND LIBERATION, FIGHTING TO END HIV, TUBERCULOSIS (TB), AND HEPATITIS C VIRUS (HCV).TAG CATALYZES OPEN COLLECTIVE ACTION BY AFFECTED COMMUNITIES, SCIENTISTS, AND POLICYMAKERS TO ENSURE THAT ALL PEOPLE LIVING WITH OR IMPACTED BY HIV, TB, OR HCV - ESPECIALLY COMMUNITIES OF COLOR AND OTHER MARGINALIZED COMMUNITIES EXPERIENCING INEQUITIES - RECEIVE LIFE-SAVING PREVENTION, DIAGNOSIS, TREATMENT, CARE, AND INFORMATION.WE ARE SCIENCE-BASED ACTIVISTS WORKING TO EXPAND AND ACCELERATE VITAL RESEARCH AND EFFECTIVE COMMUNITY ENGAGEMENT WITH RESEARCH AND POLICY INSTITUTIONS FOR AN END TO THE HIV, TB, AND HCV PANDEMICS.

  • SEE SCHEDULE OTUBERCULOSIS (TB) PROGRAMACCORDING TO THE LATEST REPORT FROM THE WORLD HEALTH ORGANIZATION (WHO), "TB REMAINED THE WORLD'S SECOND LEADING CAUSE OF DEATH FROM A SINGLE INFECTIOUS AGENT IN 2022, AFTER COVID-19, AND GLOBAL TB TARGETS HAVE EITHER BEEN MISSED OR REMAIN OFF TRACK. THE REPORTED GLOBAL NUMBER OF PEOPLE NEWLY DIAGNOSED WITH TB WAS 7.5 MILLION IN 2022. THIS IS THE HIGHEST NUMBER SINCE WHO BEGAN GLOBAL TB MONITORING IN 1995, ABOVE THE PRE-COVID BASELINE (AND PREVIOUS HISTORICAL PEAK) OF 7.1 MILLION IN 2019, AND UP FROM 5.8 MILLION IN 2020 AND 6.4 MILLION IN 2021... GLOBALLY IN 2022, TB CAUSED AN ESTIMATED 1.30 MILLION DEATHS (95% UI: 1.18-1.43 MILLION). [THIS TOTAL INCLUDES 167 000 DEATHS FROM TB AMONG PEOPLE WITH HIV, WHICH ARE OFFICIALLY CLASSIFIED AS DEATHS FROM HIV/AIDS.] THIS WAS DOWN FROM BEST ESTIMATES OF 1.4 MILLION IN BOTH 2020 AND 2021 AND ALMOST BACK TO THE LEVEL OF 2019. COVID-RELATED DISRUPTIONS ARE ESTIMATED TO HAVE RESULTED IN ALMOST HALF A MILLION EXCESS DEATHS FROM TB IN THE THREE YEARS 2020-2022, COMPARED WITH THE NUMBER THAT WOULD HAVE OCCURRED IF PRE-PANDEMIC TRENDS HAD BEEN MAINTAINED. THE NET REDUCTION IN THE GLOBAL NUMBER OF DEATHS CAUSED BY TB FROM 2015 TO 2022 WAS 19%, FAR FROM THE WHO END TB STRATEGY MILESTONE OF A 75% REDUCTION BY 2025.... WORLDWIDE, AN ESTIMATED 10.6 MILLION PEOPLE (95% UI: 9.9-11.4 MILLION) DEVELOPED TB IN 2022, UP FROM BEST ESTIMATES OF 10.3 MILLION IN 2021 AND 10.0 MILLION IN 2020.... THE GLOBAL GAP BETWEEN THE ESTIMATED NUMBER OF PEOPLE DEVELOPING TB (INCIDENT CASES) AND THE REPORTED NUMBER OF PEOPLE NEWLY DIAGNOSED WITH TB (NOTIFIED CASES) NARROWED TO A BEST ESTIMATE OF 3.1 MILLION IN 2022, DOWN FROM AROUND 4 MILLION IN BOTH 2020 AND 2021 AND BACK TO THE PRE-PANDEMIC LEVEL OF 2019. GLOBALLY, AN ESTIMATED 410 000 PEOPLE (95% UI: 370 000- 450 000) DEVELOPED MULTIDRUG-RESISTANT OR RIFAMPICIN- RESISTANT TB (MDR/RR-TB) IN 2022. THE NUMBER OF PEOPLE DIAGNOSED AND STARTED ON TREATMENT WAS MUCH LOWER: 175 650 PEOPLE IN 2022, EQUIVALENT TO ABOUT TWO IN FIVE OF THOSE IN NEED AND STILL BELOW THE PRE-PANDEMIC LEVEL OF 181 533 PEOPLE IN 2019. GLOBAL TARGETS SET AT THE FIRST UN HIGH-LEVEL MEETING ON TB FOR THE 5-YEAR PERIOD 2018-2022 WERE NOT ACHIEVED. TREATMENT SUCCESS RATES HAVE IMPROVED: TO 88% FOR PEOPLE TREATED FOR DRUG-SUSCEPTIBLE TB AND 63% FOR PEOPLE WITH MDR/RR-TB." THOUGH PREVENTABLE AND CURABLE, TUBERCULOSIS (TB) IS THE LEADING CAUSE OF DEATH OF PEOPLE WITH HIV AND ONCE AGAIN THE LEADING INFECTIOUS KILLER GLOBALLY NOW THAT THE ACUTE PHASE OF THE COVID-19 PANDEMIC HAS ABATED. RECOGNIZING THAT MUCH MORE PROGRESS COULD BE MADE IF EXISTING TOOLS WERE FULLY IMPLEMENTED, AND THAT MORE RESEARCH IS NEEDED TO END TB, TAG'S TB PROGRAM STRENGTHENS EVIDENCE-DRIVEN AND HUMAN RIGHTS-BASED ADVOCACY BOTH FOR BETTER TB RESEARCH, AND FOR HIGH-QUALITY PROGRAMS AND POLICIES WORLDWIDE, THAT MEET THE NEEDS OF AFFECTED COMMUNITIES.TAG'S TB PROGRAM EDUCATES, MOBILIZES, AND EMPOWERS COMMUNITIES TO INCREASE UNDERSTANDING OF TB AND TO CATALYZE ACTION TO REDUCE NEW INFECTIONS, DEATHS, AND SUFFERING FROM TB AND TB/HIV. THE PROGRAM WORKS WITH COMMUNITY ADVOCATES, COMMUNITY ADVISORY BOARDS, RESEARCHERS, POLICY MAKERS, DEVELOPERS, AND DONORS TO ENSURE NEEDS-DRIVEN RESEARCH TO IMPROVE OPTIONS FOR TB PREVENTION, DIAGNOSIS, AND TREATMENT. THE TB PROGRAM PUBLISHES AN ANNUAL REPORT ON TB RESEARCH FUNDING TRENDS, AND ADVOCATES FOR ALL GOVERNMENTS OF THE WORLD TO STEP UP AND CONTRIBUTE THEIR "FAIR SHARE" INVESTMENTS IN TB R&D.THE TB PROGRAM WORKS WITH RESEARCHERS, ACTIVISTS, AND POLICYMAKERS AROUND THE WORLD TO ENSURE TRANSPARENCY AND UNIVERSAL, EQUITABLE, AFFORDABLE ACCESS TO PROVEN INTERVENTIONS, FROM EARLY IN THE RESEARCH PROCESS THROUGH REGULATORY APPROVAL TO GLOBAL AND NATIONAL GUIDELINES DEVELOPMENT AND PRODUCT PRICING. TAG'S POLICY TEAM SUPPORTS THE TB PROGRAM IN EDUCATING U.S. LEGISLATORS AND OFFICIALS ON TB PRIORITIES, AND LEADS DOMESTIC WORK AT THE LOCAL, STATE, AND NATIONAL LEVEL TO SUPPORT AMBITIOUS AND EVIDENCE-BASED PROGRAMMING TO END.

    Expenses $1,558,117 · Grants $282,608 · Revenue $43,188

  • Withheld by Nonprofiteer: this text may name a private individual.

    Expenses $723,383 · Grants $8,350

  • SEE SCHEDULE OHEPATITIS C VIRUS (HCV) PROGRAMACCORDING TO THE WORLD HEALTH ORGANIZATION'S GLOBAL HEPATITIS REPORT 2024, OF THE 50 MILLION PEOPLE ESTIMATED TO BE LIVING WITH CHRONIC HEPATITIS C VIRUS INFECTION, ONLY 36% WERE DIAGNOSED BETWEEN 2015 AND 2022, AND 20% RECEIVED TREATMENT. IN 2022 ALONE, ABOUT 1 MILLION NEW HCV INFECTIONS AND APPROXIMATELY 221 000 HCV-RELATED DEATHS WERE REGISTERED, MOSTLY FROM CIRRHOSIS AND HEPATOCELLULAR CARCINOMA. ABOUT 2.3 MILLION PEOPLE (6.2%) OF THE ESTIMATED 37.7 MILLION LIVING WITH HIV GLOBALLY IN 2020 HAD SEROLOGICAL EVIDENCE OF PAST OR PRESENT HCV INFECTION. TAG'S HCV PROGRAM HAS BEEN AT THE FOREFRONT OF A GLOBAL HCV EDUCATION AND ADVOCACY MOVEMENT, WORKING IN COLLABORATION WITH AFFECTED COMMUNITIES, SCIENTISTS, GOVERNMENT, AND DRUG COMPANIES TO MAKE LIFE-SAVING INFORMATION, HIGH QUALITY AND AFFORDABLE TESTING AND CURES, AND SUPPORTIVE ENVIRONMENTS FOR UNDERSERVED POPULATIONS UNIVERSALLY AVAILABLE. THIS INCLUDES TRACKING THE PIPELINE FOR HCV INNOVATIONS, INCLUDING THE LATEST PANGENOTYPIC TREATMENTS, DIAGNOSTICS, AND LONG-ACTING INJECTABLES, AND INCREASING COMMUNITIES' DIAGNOSTICS AND TREATMENT LITERACY. GLOBALLY, TAG PROVIDES TECHNICAL ASSISTANCE TO BUILD LEADERSHIP CAPACITY FOR ADVANCING NATIONAL ELIMINATION CAMPAIGNS AND AMPLIFYING COMMUNITY VOICES-ESPECIALLY THOSE OF KEY POPULATIONS SUCH AS PEOPLE WHO USE DRUGS, SEX WORKERS, PRISONERS, MIGRANTS, AND MEN WHO HAVE SEX WITH MEN IN PLANNING AND POLICY DEVELOPMENT.TAG'S HCV PROGRAM WORKS TO OVERCOME BARRIERS TO HCV PREVENTION AND CARE, INCLUDING LIMITED DONOR FUNDING FOR HCV, RESTRICTIONS IMPOSED BY GOVERNMENTS AND PAYERS, PATENT, AND PRICING BARRIERS, LIMITED VOLUNTARY LICENSING AND DELAYS IN DRUG REGISTRATION BY ORIGINATOR COMPANIES. THE HCV PROGRAM ADVOCATES FOR HARM REDUCTION AND DRUG DECRIMINALIZATION EFFORTS, INCLUDING SUPPORT FOR OVERDOSE PREVENTION AND SAFE CONSUMPTION SITES AS UNSAFE INJECTION DRUG USE IS A MAJOR ROUTE OF HCV TRANSMISSION.IN THE U.S., TAG'S POLICY TEAM WORKS AT THE LOCAL, STATE, AND NATIONAL LEVELS: ADVOCATING FOR VIRAL HEPATITIS FUNDING, CHAMPIONING TREATMENT COVERAGE FOR PEOPLE WHO USE DRUGS, PEOPLE WHO ARE UNSTABLY HOUSED AND INCARCERATED OR OTHERWISE MARGINALIZED PEOPLE, ENCOURAGING VOLUME-BASED PRICING DEALS FOR DAAS, STRENGTHENING NATIONAL SURVEILLANCE, AND SUPPORTING COMMUNITY ENGAGEMENT. TAG'S ADVOCACY HELPED ADVANCE COVERAGE FOR UNIVERSAL ADULT HCV SCREENING AND DRIVE NEW YORK STATE'S COMMITMENT TO ELIMINATE HCV -- THE FIRST IN THE NATION! -- WITH TAG PARTICIPATING IN THE RESULTANT STATEWIDE HCV ELIMINATION TASK FORCE.

    Expenses $323,533 · Grants $6,000

  • SEE SCHEDULE OUS & GLOBAL HEALTH POLICY PROGRAMTAG US AND GLOBAL HEALTH POLICY PROGRAM STAFF WORK WITH PROGRAM TEAMS TO DEVELOP SPECIFIC POLICY GOALS AND STRATEGIES TO ADVANCE THE END OF THE HIV, TUBERCULOSIS (TB), AND HEPATITIS C (HCV) EPIDEMICS. THIS INCLUDES SECURING FUNDING FOR, AND SHAPING POLICY RELATED TO, GOVERNMENT AND MULTILATERAL PROGRAMS THAT PROVIDE DIRECT SERVICES, ISSUE GUIDELINES, COORDINATE ADMINISTRATION, AND CONDUCT RESEARCH ON EACH OF TAG'S PRIORITY HEALTH AREAS. WORKING WITH PARTNERS IN THE PUBLIC AND PRIVATE SECTORS, THE POLICY PROGRAM ADVANCES A HUMAN-RIGHTS BASED APPROACH TO EVIDENCE-INFORMED POLICY. THIS INVOLVES EDUCATING STAKEHOLDERS AND DECISION MAKERS; AUTHORING POLICY BRIEFS CONTAINING INFORMATION AND RECOMMENDATIONS; CONVENING PARTNERS; LEADING AND CONTRIBUTING TO COALITIONS; SUBMITTING TESTIMONY, PUBLIC COMMENTS, REPORT LANGUAGE, AND POLICY PROPOSALS; PROVIDING TECHNICAL ASSISTANCE AND CAPACITY BUILDING; AND FACILITATING ADVOCACY OPPORTUNITIES FOR COMMUNITIES MOST DIRECTLY AFFECTED BY THE POLICIES CONCERNED.

    Expenses $359,670

As filed on the 2023 return. The filer continues this part on Schedule O, which is not shown here. A text marked withheld matched a screen for wording that may name a private individual, such as an honorific or "in memory of". Most of what it withholds names no one; it is withheld so that what does is never shown.

Listed in Part VII

  • Robert W Lennon

    PRESIDENT

    Total calculated
    $0
    Hours/week
    3.5
  • Ivy Kwan Arce

    TREASURER

    Total calculated
    $0
    Hours/week
    4.5
  • Mrinal Vikram

    SECRETARY

    Total calculated
    $0
    Hours/week
    2
  • Jim Aquino

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1
  • Moe Ari Brownleft 1023

    DIRECTOR

    Total calculated
    $0
    Hours/week
    0.5
  • Nick Debs

    DIRECTOR

    Total calculated
    $0
    Hours/week
    0.5
  • Joy Episalla

    DIRECTOR

    Total calculated
    $0
    Hours/week
    3.5
  • Kevin Goetz

    DIRECTOR

    Total calculated
    $0
    Hours/week
    3
  • Jameel Jiwani

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1
  • Richard Lynn PhD

    DIRECTOR

    Total calculated
    $0
    Hours/week
    4
  • Robert Monteleone

    DIRECTOR

    Total calculated
    $0
    Hours/week
    2.5
  • Laura Morrison

    DIRECTOR

    Total calculated
    $0
    Hours/week
    2.5
  • David Puente

    DIRECTOR

    Total calculated
    $0
    Hours/week
    3.5
  • Michael Monteroleft 1023

    DIRECTOR

    Total calculated
    $0
    Hours/week
    0
  • Mark Harrington

    EXECUTIVE DIRECTOR

    Total calculated
    $192,456
    From this org
    $174,202
    From related orgs
    $0
    Other
    $18,254
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $174,202
    Bonus
    $0
    Other
    $0
    Deferred
    $0
    Nontaxable benefits
    $18,254
    Filer's total
    $192,456
  • Jason Kirk

    CHIEF OPERATING OFFICER

    Total calculated
    $132,904
    From this org
    $114,650
    From related orgs
    $0
    Other
    $18,254
    Hours/week
    40
  • Lindsay McKenna

    TB PROGRAM CO-DIRECTOR

    Total calculated
    $124,164
    From this org
    $105,910
    From related orgs
    $0
    Other
    $18,254
    Hours/week
    40
  • Mike Frick

    TB PROGRAM CO-DIRECTOR

    Total calculated
    $124,164
    From this org
    $105,910
    From related orgs
    $0
    Other
    $18,254
    Hours/week
    40
  • Christopher George

    DIRECTOR OF FINANCE

    Total calculated
    $104,500
    From this org
    $104,500
    From related orgs
    $0
    Other
    $0
    Hours/week
    40

Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.

Schedule J

Answered yes

  • 3 · Approval by the board or compensation committee

Answered no

  • 4a · Severance or change-of-control payment
  • 4b · Supplemental nonqualified retirement plan
  • 4c · Equity-based compensation arrangement
  • 5a · Pay contingent on this organization's revenues
  • 5b · Pay contingent on a related organization's revenues
  • 6a · Pay contingent on this organization's net earnings
  • 6b · Pay contingent on a related organization's net earnings
  • 7 · Other non-fixed payments
  • 8 · Paid under the initial-contract exception

Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.

Grants on this return

Fundraising and gaming

From Schedule G of this return, as filed.

Had an agreement with a professional fundraiser (line 2a)
Not answered

Fundraising events (Part II)

Part II has at most four columns: the two largest events, the rest together, and the total.

Line Event 1 RIAA Total
Gross receipts (line 1) $242,151 $242,151
Less contributions (line 2) $204,526 $204,526
Gross income (line 3) $37,625 $37,625
Cash prizes (line 4) — —
Noncash prizes (line 5) — —
Rent and facility costs (line 6) $14,625 $14,625
Food and beverages (line 7) $23,000 $23,000
Entertainment (line 8) — —
Other direct expenses (line 9) — —
Direct expenses (line 10)
$37,625
Net income (line 11)
$0

Activities outside the United States

From Schedule F of this return, as filed.

Offices (line 3c)
0
Employees, agents and contractors (line 3c)
0
Expenditures and investments (line 3c)
$425,510

At most 25 lines of each part are listed here. Schedule F names no grantee, so each line is a region and its money.

Activities by region (Part I)

Region Offices Employees Activity Specific services Expenditures
CENTRAL AMERICA AND THE CARIBBEAN 0 0 PROGRAM SERVICES HCV - LAT CAB $450
EUROPE (INCLUDING ICELAND AND GREENLAND) 0 0 PROGRAM SERVICES TB - UNION CONFERENCE - PARIS $92,457
EUROPE (INCLUDING ICELAND AND GREENLAND) 0 0 PROGRAM SERVICES POLICY - AMR MEETING - ROME $341
SUB-SAHARAN AFRICA 0 0 PROGRAM SERVICES REGIONAL CAB SUPPORT $57,069
EAST ASIA AND THE PACIFIC 0 0 GRANTS TB ADVOCACY/CAB SUPPORT $21,173
RUSSIA AND NEIGHBORING STATES 0 0 GRANTS TB ADVOCACY/CAB SUPPORT $52,861
SOUTH ASIA 0 0 GRANTS TB ADVOCACY/CAB SUPPORT $24,978
SUB-SAHARAN AFRICA 0 0 GRANTS TB ADVOCACY/CAB SUPPORT $170,181
SUB-SAHARAN AFRICA 0 0 GRANTS HCV - LAT CAB/CONSULTANCY $6,000

Grants to organizations, by region (Part II)

The purpose of each grant is not shown.

Region Cash grants Manner of disbursement Noncash assistance Noncash description Valuation
EAST ASIA AND THE PACIFIC $21,173 BANK WIRE $0 — —
RUSSIA AND NEIGHBORING STATES $52,861 BANK WIRE $0 — —
SOUTH ASIA $12,500 BANK WIRE $0 — —
SOUTH ASIA $12,478 BANK WIRE $0 — —
SUB-SAHARAN AFRICA $59,068 BANK WIRE $0 — —
SUB-SAHARAN AFRICA $25,000 BANK WIRE $0 — —
SUB-SAHARAN AFRICA $25,000 BANK WIRE $0 — —
SUB-SAHARAN AFRICA $25,595 BANK WIRE $0 — —
SUB-SAHARAN AFRICA $25,000 BANK WIRE $0 — —

Grants to individuals, by region (Part III)

The type of assistance is not shown.

Region Recipients Cash grants Manner of disbursement Noncash assistance
SUB-SAHARAN AFRICA 1 $6,000 BANK WIRE —
Transferred property to a foreign corporation during the year (line 1)
No
Had an interest in a foreign trust (line 2)
No
Owned an interest in a foreign corporation (line 3)
No
Was a shareholder of a passive foreign investment company or qualified electing fund (line 4)
No
Owned an interest in a foreign partnership (line 5)
No
Had operations in or related to a boycotting country (line 6)
No

Provenance

Return type
form_990
Tax year
2023
Filed
4 November 2024
IRS schema version
2023v5.1
Source object
202403129349302165

Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.

The source document this was parsed from is served over the API, which is where bulk and document access live.